LISTING OF CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-42 (canceled).

43-44 (canceled).

45. (Previously Presented) A method for treating metastatic melanoma in a patient in need thereof, comprising administering a therapeutically effective amount of a selective endothelin B receptor (ETB) antagonist to said patient, with the proviso that said method does not include gene therapy.

46. (Canceled).

47. (Canceled).

48. (Previously Presented) The method of claim 45, wherein the selective endothelin B receptor (ETB) antagonist is a peptide inhibitor.

49. (Previously Presented) The method of claim 45, wherein the selective endothelin B receptor (ETB) antagonist is an endothelin B receptor (ETB) antibody.

50. (Canceled).

51. (Canceled).

52. (Canceled).

53. (Previously Presented) The method of claim 45, wherein the selective endothelin B receptor (ETB) antagonist is BQ788.

54. (Previously Presented) The method of claim 45, wherein the selective endothelin B receptor (ETB) antagonist is IRL-1038.

55. (Previously Presented) The method of claim 45, wherein the selective endothelin B receptor (ETB) antagonist is RES-701-1.

56. (Canceled).

57. (Previously Presented) The method of claim 45, wherein said patient displays one or more atypical moles.

58. (Canceled).

59. (Previously Presented) The method of claim 45, wherein the ability of the selective endothelin B receptor (ETB) antagonist to antagonize the endothelin B receptor (ETB) is determined *in vitro* by:

a) contacting a cell culture expressing endothelin B receptor (ETB) and E-cadherin with endothelin and the compound;

b) determining the level of E-cadherin expression; and

c) comparing the level of E-cadherin expression determined in step b) to that of a control culture in the absence of said compound, so that an increase in expression of E-cadherin indicates antagonist activity.

60-68. (Canceled)

69. (Currently Amended) A method for ~~preventing~~ inhibiting the development of metastatic melanoma in a patient ~~diagnosed with~~ having melanoma, comprising administering a therapeutically effective amount of a selective endothelin B receptor (ETB) antagonist to said patient, with the proviso that said method does not include gene therapy.

70. (Previously Presented) The method of claim 69, wherein the selective endothelin B receptor (ETB) antagonist is a peptide inhibitor.

71. (Previously Presented) The method of claim 69, wherein the selective endothelin B receptor (ETB) antagonist is an endothelin B receptor (ETB) antibody.

72. (Previously Presented) The method of claim 69, wherein the selective endothelin B receptor (ETB) antagonist is BQ788.

73. (Previously Presented) The method of claim 69, wherein the selective endothelin B receptor (ETB) antagonist is IRL-1038.

74. (Previously Presented) The method of claim 69, wherein the selective endothelin B receptor (ETB) antagonist is RES-701-1.

75. (Previously Presented) The method of claim 69, wherein said patient displays one or more atypical moles.

76. (Previously Presented) The method of claim 69, wherein the ability of the selective endothelin B receptor (ETB) antagonist to antagonize the endothelin B receptor (ETB) is determined *in vitro* by:

a) contacting a cell culture expressing endothelin B receptor (ETB) and E-cadherin with endothelin and the compound;

b) determining the level of E-cadherin expression; and

c) comparing the level of E-cadherin expression determined in step b) to that of a control culture in the absence of said compound, so that an increase in expression of E-cadherin indicates antagonist activity.